Collaborations and Other Arrangements (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration:



	Product Status			Milestones (Deferred) Capitalized ⁽¹⁾
Product Family	U.S.	Europe	Japan	Year	Amount
Trajenta ⁽²⁾	Launched 2011	Launched 2011	Launched 2011	2016	$	—
				2015	—
				Cumulative ⁽⁵⁾	446.4
Jardiance ⁽³⁾	Launched 2014	Launched 2014	Launched 2015	2016	—
				2015	—
				Cumulative ⁽⁵⁾	299.5
Basaglar	Approved ⁽⁴⁾	Launched 2015	Launched 2015	2016	(187.5		)
				2015	—
				Cumulative ⁽⁵⁾	(250.0		)

⁽¹⁾ In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.

⁽²⁾ Jentadueto is included in the Trajenta family of product results.

⁽³⁾ Glyxambi and Synjardyare included in the Jardiance family of product results.

⁽⁴⁾ In September 2015, we entered into a settlement agreement to resolve patent infringement litigation filed by Sanofi-Aventis U.S. LLC, which markets Lantus^®(insulin glargine). As part of the settlement agreement, the parties agreed that Basaglar can be launched in the U.S. beginning on December 15, 2016. Basaglar received U.S. Food and Drug Administration (FDA) approval in December 2015. As a result of receiving FDA approval, we received a $187.5 million milestone payment from Boehringer Ingelheim in the first quarter of 2016, which was recorded as deferred revenue and, upon product launch, will be amortized through the term of the collaboration to collaboration and other revenue.

⁽⁵⁾ The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration.

Bi Compounds [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Trajenta	$	115.4	$	92.7	$	330.8	$	255.0
Jardiance	47.5		15.4		125.8		45.7

Erbitux [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our revenue recognized with respect to Erbitux:



	Three Months Ended September 30,					Nine Months Ended September 30,
	2016		2015			2016		2015
Net product revenues - BMS	$	—	$	(2.3	)	$	—	$	22.6
Net product revenues - third party	155.9		—			455.8		—
Collaboration and other revenue	28.7		88.2			77.5		286.2
Revenue	$	184.6	$	85.9		$	533.3	$	308.8

Effient [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our revenue recognized with respect to Effient:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Revenue	$	127.7	$	132.1	$	394.3	$	382.7

Selling, General and Administrative Expenses [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described above:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Marketing, selling, and administrative	$	47.4	$	53.6	$	143.7	$	156.5

Collaborative Arrangement [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our collaboration and other revenue, which is included in revenue in the consolidated condensed statements of operations:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Collaboration and other revenue	$	216.5	$	215.2	$	607.3	$	644.7

Erbitux Acquisition [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at October 1, 2015
Marketed products ⁽¹⁾	$	602.1
Deferred tax asset	232.2
Deferred tax liability	(228.2		)
Other assets and liabilities - net	57.2
Total identifiable net assets	$	663.3
Total consideration - contingent consideration liability ⁽²⁾	$	(663.3	)

⁽¹⁾These intangible assets are being amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018.

⁽²⁾See Note 6 for discussion on the estimation of the contingent consideration liability.